A new post-hoc analysis of the Bezafibrate Infarction Prevention (BIP) trial identified 1470 patients with MS and revealed that in those patients treatment with bezafibrate (400 mg/d) was associated with a reduced risk of MI as compared with placebo, and cardiac mortality showed borderline significance towards reduction ( Tenenbaum et al 2005 ).
2
—
—
The sentences
In addition, endothelial function improved in the Mediterranean diet group but remained stable in the control group, although this difference was not quite statistically significant, suggesting a potential mechanistic explanation of benefit.